| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 68 | 2025 | 222 | 12.930 |
Why?
|
| Rhinitis | 63 | 2025 | 186 | 9.990 |
Why?
|
| Rhinitis, Allergic, Seasonal | 107 | 2016 | 179 | 9.830 |
Why?
|
| Nasal Polyps | 22 | 2024 | 64 | 6.500 |
Why?
|
| Rhinitis, Allergic, Perennial | 47 | 2014 | 81 | 5.190 |
Why?
|
| Nasal Mucosa | 94 | 2014 | 196 | 5.160 |
Why?
|
| Nasal Provocation Tests | 85 | 2013 | 129 | 4.420 |
Why?
|
| Allergens | 48 | 2016 | 191 | 3.350 |
Why?
|
| Hypersensitivity | 37 | 2021 | 166 | 3.210 |
Why?
|
| Anti-Allergic Agents | 17 | 2019 | 38 | 3.030 |
Why?
|
| Nose | 20 | 2013 | 96 | 2.740 |
Why?
|
| Histamine | 48 | 2013 | 124 | 2.400 |
Why?
|
| Humidity | 29 | 2008 | 94 | 2.320 |
Why?
|
| Nasal Cavity | 23 | 2013 | 94 | 2.180 |
Why?
|
| Androstadienes | 11 | 2013 | 74 | 1.860 |
Why?
|
| Chronic Disease | 41 | 2025 | 983 | 1.850 |
Why?
|
| Pneumococcal Infections | 11 | 2008 | 52 | 1.850 |
Why?
|
| Anti-Inflammatory Agents | 18 | 2025 | 358 | 1.770 |
Why?
|
| Rhinitis, Allergic | 11 | 2024 | 52 | 1.740 |
Why?
|
| Histamine H1 Antagonists | 19 | 2003 | 39 | 1.730 |
Why?
|
| Administration, Intranasal | 40 | 2020 | 140 | 1.680 |
Why?
|
| Air | 19 | 2008 | 63 | 1.680 |
Why?
|
| Immunoglobulin E | 24 | 2020 | 152 | 1.580 |
Why?
|
| Histamine Release | 37 | 2008 | 53 | 1.580 |
Why?
|
| Double-Blind Method | 62 | 2020 | 1791 | 1.480 |
Why?
|
| Eosinophils | 26 | 2020 | 196 | 1.470 |
Why?
|
| Humans | 309 | 2025 | 95800 | 1.420 |
Why?
|
| Endoscopy | 11 | 2025 | 374 | 1.270 |
Why?
|
| Maxillary Sinusitis | 5 | 2015 | 14 | 1.240 |
Why?
|
| Loratadine | 12 | 2013 | 21 | 1.210 |
Why?
|
| Cross-Over Studies | 26 | 2016 | 397 | 1.180 |
Why?
|
| Paranasal Sinuses | 17 | 2025 | 62 | 1.180 |
Why?
|
| Asthma | 19 | 2021 | 1051 | 1.150 |
Why?
|
| Biological Products | 4 | 2021 | 179 | 1.140 |
Why?
|
| Conjunctivitis, Allergic | 4 | 2009 | 9 | 1.120 |
Why?
|
| Adult | 146 | 2025 | 28578 | 1.090 |
Why?
|
| Cold Temperature | 18 | 2007 | 162 | 1.060 |
Why?
|
| Pollen | 28 | 2013 | 87 | 1.030 |
Why?
|
| Antigens | 25 | 2001 | 231 | 1.020 |
Why?
|
| Hot Temperature | 8 | 2008 | 217 | 1.010 |
Why?
|
| Male | 138 | 2025 | 45686 | 0.980 |
Why?
|
| Eye | 4 | 2013 | 112 | 0.980 |
Why?
|
| Female | 143 | 2025 | 49872 | 0.970 |
Why?
|
| Streptococcus pneumoniae | 10 | 2006 | 56 | 0.970 |
Why?
|
| Sneezing | 25 | 2011 | 36 | 0.920 |
Why?
|
| Maxillary Sinus | 6 | 2013 | 21 | 0.910 |
Why?
|
| Terfenadine | 14 | 2024 | 23 | 0.910 |
Why?
|
| Otolaryngology | 4 | 2014 | 56 | 0.900 |
Why?
|
| Peptide Hydrolases | 40 | 1997 | 100 | 0.860 |
Why?
|
| Glucocorticoids | 11 | 2014 | 369 | 0.850 |
Why?
|
| Nasal Lavage Fluid | 14 | 2012 | 26 | 0.790 |
Why?
|
| Eosinophilia | 4 | 2017 | 88 | 0.790 |
Why?
|
| Budesonide | 5 | 2014 | 46 | 0.760 |
Why?
|
| Pregnadienediols | 4 | 2022 | 13 | 0.740 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 1021 | 0.730 |
Why?
|
| Insurance | 1 | 2022 | 12 | 0.720 |
Why?
|
| Reflex | 9 | 2013 | 81 | 0.710 |
Why?
|
| Quinolines | 6 | 2010 | 89 | 0.700 |
Why?
|
| Kinins | 28 | 1997 | 31 | 0.700 |
Why?
|
| Dibenzoxepins | 2 | 2013 | 5 | 0.690 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 7 | 2024 | 15 | 0.650 |
Why?
|
| Beclomethasone | 8 | 1998 | 16 | 0.650 |
Why?
|
| Quality of Life | 20 | 2023 | 1816 | 0.630 |
Why?
|
| Antibodies, Anti-Idiotypic | 7 | 2017 | 44 | 0.620 |
Why?
|
| Nasal Obstruction | 6 | 2011 | 21 | 0.620 |
Why?
|
| Middle Aged | 85 | 2025 | 28208 | 0.620 |
Why?
|
| Epinephrine | 1 | 2020 | 92 | 0.620 |
Why?
|
| Mast Cells | 25 | 2002 | 97 | 0.620 |
Why?
|
| Tonsillectomy | 3 | 2016 | 31 | 0.590 |
Why?
|
| Adrenal Cortex Hormones | 10 | 2022 | 294 | 0.590 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 22 | 0.570 |
Why?
|
| Mucociliary Clearance | 3 | 2011 | 7 | 0.560 |
Why?
|
| Biological Therapy | 1 | 2018 | 47 | 0.560 |
Why?
|
| Temperature | 7 | 2007 | 426 | 0.550 |
Why?
|
| Methacholine Chloride | 12 | 2008 | 67 | 0.550 |
Why?
|
| Ipratropium | 6 | 2003 | 18 | 0.550 |
Why?
|
| Water | 4 | 2011 | 307 | 0.550 |
Why?
|
| Adenoidectomy | 3 | 2016 | 23 | 0.540 |
Why?
|
| Inhalation | 3 | 2010 | 34 | 0.540 |
Why?
|
| Anesthesia, Inhalation | 3 | 2013 | 37 | 0.520 |
Why?
|
| Nasal Sprays | 4 | 2016 | 9 | 0.520 |
Why?
|
| Immunologic Factors | 1 | 2018 | 175 | 0.510 |
Why?
|
| Adolescent | 53 | 2016 | 9873 | 0.510 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 1827 | 0.510 |
Why?
|
| Ambrosia | 7 | 2012 | 14 | 0.500 |
Why?
|
| Methyl Ethers | 2 | 2013 | 34 | 0.500 |
Why?
|
| Anesthesia, Intravenous | 2 | 2013 | 36 | 0.500 |
Why?
|
| Oxymetazoline | 6 | 2011 | 10 | 0.500 |
Why?
|
| Mometasone Furoate | 7 | 2025 | 19 | 0.500 |
Why?
|
| Ovalbumin | 6 | 2006 | 110 | 0.500 |
Why?
|
| Forehead | 1 | 2016 | 15 | 0.490 |
Why?
|
| Nasal Decongestants | 2 | 2011 | 10 | 0.490 |
Why?
|
| Skull Neoplasms | 1 | 2016 | 27 | 0.490 |
Why?
|
| Acetates | 5 | 2010 | 67 | 0.490 |
Why?
|
| Retinoblastoma | 1 | 2016 | 31 | 0.490 |
Why?
|
| Propofol | 2 | 2013 | 95 | 0.490 |
Why?
|
| Pain, Postoperative | 3 | 2016 | 277 | 0.480 |
Why?
|
| Respiratory Mechanics | 3 | 2011 | 114 | 0.480 |
Why?
|
| Blood Loss, Surgical | 2 | 2013 | 133 | 0.480 |
Why?
|
| Atropine | 7 | 1996 | 61 | 0.470 |
Why?
|
| Cellulose | 1 | 2016 | 59 | 0.470 |
Why?
|
| Leukotriene Antagonists | 6 | 2010 | 25 | 0.470 |
Why?
|
| Mycoses | 1 | 2016 | 47 | 0.470 |
Why?
|
| Cytokines | 4 | 2018 | 871 | 0.470 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2016 | 2773 | 0.470 |
Why?
|
| Analgesics | 1 | 2016 | 132 | 0.460 |
Why?
|
| Papilloma, Inverted | 1 | 2015 | 6 | 0.460 |
Why?
|
| Osteosarcoma | 1 | 2016 | 160 | 0.450 |
Why?
|
| Aspergillosis | 1 | 2015 | 39 | 0.450 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2015 | 26 | 0.450 |
Why?
|
| Cancer Survivors | 1 | 2016 | 88 | 0.440 |
Why?
|
| Hypersensitivity, Immediate | 4 | 2006 | 65 | 0.430 |
Why?
|
| Neutrophils | 10 | 2001 | 328 | 0.430 |
Why?
|
| Common Cold | 6 | 2021 | 13 | 0.430 |
Why?
|
| Body Temperature | 3 | 2005 | 131 | 0.420 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 245 | 0.410 |
Why?
|
| Clinical Trials as Topic | 13 | 2020 | 1166 | 0.410 |
Why?
|
| Personnel Selection | 1 | 2014 | 64 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 1425 | 0.410 |
Why?
|
| Acute Disease | 13 | 2016 | 859 | 0.400 |
Why?
|
| Ribonucleases | 3 | 2001 | 97 | 0.400 |
Why?
|
| Nasal Septum | 5 | 2014 | 27 | 0.390 |
Why?
|
| Treatment Outcome | 23 | 2025 | 9167 | 0.390 |
Why?
|
| Education, Medical, Graduate | 2 | 2014 | 436 | 0.370 |
Why?
|
| Internship and Residency | 2 | 2014 | 1134 | 0.370 |
Why?
|
| Patient Selection | 2 | 2018 | 708 | 0.360 |
Why?
|
| Disease Models, Animal | 9 | 2007 | 2534 | 0.360 |
Why?
|
| Bronchial Provocation Tests | 8 | 2008 | 25 | 0.360 |
Why?
|
| Basophils | 15 | 1994 | 26 | 0.360 |
Why?
|
| Skin Temperature | 2 | 2003 | 16 | 0.360 |
Why?
|
| Prostaglandin D2 | 20 | 1996 | 28 | 0.350 |
Why?
|
| Albumins | 15 | 2008 | 135 | 0.350 |
Why?
|
| Prednisone | 8 | 2014 | 252 | 0.350 |
Why?
|
| Ioxaglic Acid | 1 | 2011 | 7 | 0.350 |
Why?
|
| Desensitization, Immunologic | 7 | 1995 | 46 | 0.340 |
Why?
|
| Th2 Cells | 4 | 2020 | 151 | 0.340 |
Why?
|
| Leukocyte Count | 11 | 2012 | 217 | 0.330 |
Why?
|
| Mice, Inbred BALB C | 8 | 2006 | 1124 | 0.330 |
Why?
|
| Cetirizine | 8 | 2013 | 12 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2013 | 1965 | 0.330 |
Why?
|
| Comorbidity | 6 | 2023 | 1011 | 0.330 |
Why?
|
| Mice | 18 | 2008 | 12537 | 0.320 |
Why?
|
| Eye Diseases | 2 | 2008 | 59 | 0.320 |
Why?
|
| Maxillary Diseases | 1 | 2010 | 3 | 0.320 |
Why?
|
| Tooth Extraction | 1 | 2010 | 11 | 0.320 |
Why?
|
| Pulmonary Ventilation | 2 | 2011 | 33 | 0.310 |
Why?
|
| Vitamin D | 2 | 2010 | 273 | 0.310 |
Why?
|
| Bradykinin | 6 | 1995 | 46 | 0.310 |
Why?
|
| Olfactory Mucosa | 2 | 2010 | 33 | 0.300 |
Why?
|
| Reflex, Abnormal | 1 | 2009 | 7 | 0.300 |
Why?
|
| Biomarkers | 10 | 2019 | 1931 | 0.300 |
Why?
|
| Conjunctiva | 1 | 2009 | 17 | 0.300 |
Why?
|
| Foreign Bodies | 1 | 2010 | 66 | 0.300 |
Why?
|
| Cysts | 1 | 2010 | 104 | 0.290 |
Why?
|
| Analysis of Variance | 10 | 2006 | 908 | 0.290 |
Why?
|
| Job Application | 1 | 2008 | 18 | 0.290 |
Why?
|
| Animals | 25 | 2016 | 28889 | 0.280 |
Why?
|
| Flow Cytometry | 7 | 2014 | 726 | 0.280 |
Why?
|
| Calcinosis | 1 | 2010 | 232 | 0.280 |
Why?
|
| Time Factors | 24 | 2013 | 5561 | 0.280 |
Why?
|
| Urban Health | 1 | 2008 | 55 | 0.280 |
Why?
|
| Phenoxybenzamine | 2 | 2005 | 15 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 9 | 2008 | 3491 | 0.280 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2005 | 31 | 0.280 |
Why?
|
| Ciprofloxacin | 1 | 2008 | 25 | 0.280 |
Why?
|
| Foot | 3 | 2003 | 59 | 0.270 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2008 | 56 | 0.270 |
Why?
|
| Plant Proteins | 5 | 2013 | 143 | 0.270 |
Why?
|
| Surveys and Questionnaires | 12 | 2012 | 2859 | 0.270 |
Why?
|
| Inflammation | 14 | 2010 | 1063 | 0.270 |
Why?
|
| Young Adult | 10 | 2016 | 7026 | 0.260 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 249 | 0.260 |
Why?
|
| Placebos | 9 | 2019 | 213 | 0.260 |
Why?
|
| Biopsy | 5 | 2016 | 1208 | 0.260 |
Why?
|
| Algorithms | 2 | 2015 | 2015 | 0.260 |
Why?
|
| Anti-Infective Agents | 1 | 2008 | 96 | 0.260 |
Why?
|
| Drug Therapy, Combination | 6 | 2013 | 787 | 0.260 |
Why?
|
| Immunotherapy | 9 | 1995 | 766 | 0.250 |
Why?
|
| Steroids | 3 | 2011 | 173 | 0.250 |
Why?
|
| Colony Count, Microbial | 4 | 2008 | 42 | 0.250 |
Why?
|
| Capillary Permeability | 8 | 2013 | 132 | 0.250 |
Why?
|
| Respirovirus Infections | 1 | 2006 | 10 | 0.250 |
Why?
|
| Aza Compounds | 1 | 2006 | 7 | 0.240 |
Why?
|
| Environmental Pollutants | 1 | 2007 | 56 | 0.240 |
Why?
|
| Azithromycin | 1 | 2006 | 17 | 0.240 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2006 | 23 | 0.240 |
Why?
|
| Dexamethasone | 1 | 2008 | 350 | 0.240 |
Why?
|
| Atmosphere Exposure Chambers | 3 | 2001 | 7 | 0.240 |
Why?
|
| Sodium Chloride | 1 | 2006 | 88 | 0.240 |
Why?
|
| Patient Compliance | 1 | 2007 | 239 | 0.230 |
Why?
|
| Cystic Fibrosis | 4 | 2000 | 121 | 0.230 |
Why?
|
| Child | 22 | 2016 | 7618 | 0.230 |
Why?
|
| Aged | 21 | 2025 | 20848 | 0.230 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2005 | 93 | 0.220 |
Why?
|
| Phthalazines | 4 | 2008 | 53 | 0.220 |
Why?
|
| Patient Satisfaction | 2 | 2007 | 514 | 0.210 |
Why?
|
| Inflammation Mediators | 4 | 2019 | 161 | 0.210 |
Why?
|
| T-Lymphocytes | 4 | 2006 | 1310 | 0.210 |
Why?
|
| Airway Resistance | 10 | 1999 | 71 | 0.210 |
Why?
|
| Ephedrine | 3 | 2006 | 6 | 0.210 |
Why?
|
| Nose Neoplasms | 2 | 2000 | 36 | 0.200 |
Why?
|
| Hydroxyzine | 4 | 1991 | 7 | 0.200 |
Why?
|
| Th1 Cells | 4 | 2006 | 172 | 0.200 |
Why?
|
| Prostaglandins D | 14 | 1989 | 15 | 0.200 |
Why?
|
| Respiratory System | 3 | 2011 | 120 | 0.200 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 458 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 5 | 2015 | 1096 | 0.200 |
Why?
|
| Parasympathetic Nervous System | 4 | 2001 | 36 | 0.200 |
Why?
|
| Maxillary Neoplasms | 1 | 2003 | 7 | 0.200 |
Why?
|
| Carcinoma, Verrucous | 1 | 2003 | 7 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 4 | 2006 | 847 | 0.190 |
Why?
|
| Severity of Illness Index | 6 | 2012 | 1981 | 0.190 |
Why?
|
| Bacterial Infections | 1 | 2004 | 183 | 0.190 |
Why?
|
| Serum Albumin | 9 | 2002 | 127 | 0.190 |
Why?
|
| Leukotrienes | 3 | 1991 | 20 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2002 | 34 | 0.190 |
Why?
|
| Poaceae | 5 | 2011 | 19 | 0.190 |
Why?
|
| Administration, Oral | 7 | 2006 | 686 | 0.180 |
Why?
|
| Respiration Disorders | 2 | 2020 | 42 | 0.180 |
Why?
|
| Therapeutic Irrigation | 11 | 2002 | 66 | 0.180 |
Why?
|
| Research | 2 | 2001 | 265 | 0.180 |
Why?
|
| Respiratory Hypersensitivity | 6 | 1999 | 41 | 0.180 |
Why?
|
| Supine Position | 1 | 2001 | 34 | 0.180 |
Why?
|
| Middle Ear Ventilation | 2 | 1992 | 4 | 0.180 |
Why?
|
| United States | 7 | 2021 | 7764 | 0.180 |
Why?
|
| Statistics, Nonparametric | 5 | 2013 | 311 | 0.180 |
Why?
|
| Fluticasone | 6 | 2010 | 31 | 0.180 |
Why?
|
| Consensus | 3 | 2021 | 370 | 0.180 |
Why?
|
| Administration, Topical | 7 | 2008 | 86 | 0.180 |
Why?
|
| Olopatadine Hydrochloride | 2 | 2013 | 6 | 0.170 |
Why?
|
| Prospective Studies | 11 | 2013 | 4664 | 0.170 |
Why?
|
| Serine Endopeptidases | 3 | 2002 | 150 | 0.170 |
Why?
|
| Receptors, Muscarinic | 1 | 2001 | 48 | 0.170 |
Why?
|
| Disease Progression | 3 | 2015 | 1559 | 0.170 |
Why?
|
| Cyproheptadine | 6 | 1993 | 10 | 0.170 |
Why?
|
| Premedication | 4 | 1994 | 58 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2021 | 109 | 0.170 |
Why?
|
| Sublingual Immunotherapy | 1 | 2020 | 2 | 0.160 |
Why?
|
| Body Temperature Regulation | 1 | 2000 | 60 | 0.160 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2000 | 18 | 0.160 |
Why?
|
| Cholinergic Antagonists | 2 | 2003 | 30 | 0.160 |
Why?
|
| Reaction Time | 1 | 2001 | 323 | 0.160 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 4 | 0.160 |
Why?
|
| Bronchodilator Agents | 1 | 2000 | 70 | 0.160 |
Why?
|
| Hemostasis | 1 | 2020 | 24 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 350 | 0.160 |
Why?
|
| Streptococcal Infections | 1 | 2000 | 57 | 0.160 |
Why?
|
| Microbiota | 2 | 2016 | 426 | 0.160 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 56 | 0.160 |
Why?
|
| Blood Proteins | 3 | 2001 | 151 | 0.160 |
Why?
|
| Interleukin-4 | 3 | 2017 | 135 | 0.150 |
Why?
|
| Phenotype | 4 | 2016 | 2575 | 0.150 |
Why?
|
| Diagnosis, Differential | 6 | 2013 | 1615 | 0.150 |
Why?
|
| Turbinates | 4 | 2011 | 11 | 0.150 |
Why?
|
| Pharmacies | 1 | 2019 | 12 | 0.150 |
Why?
|
| Interleukin-13 | 2 | 2017 | 42 | 0.150 |
Why?
|
| Respiratory Tract Diseases | 2 | 1998 | 47 | 0.150 |
Why?
|
| Exophthalmos | 1 | 1999 | 5 | 0.150 |
Why?
|
| Orbital Neoplasms | 1 | 1999 | 16 | 0.150 |
Why?
|
| Critical Pathways | 1 | 2019 | 36 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 132 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2012 | 1957 | 0.150 |
Why?
|
| Multimorbidity | 1 | 2018 | 6 | 0.150 |
Why?
|
| Random Allocation | 9 | 2001 | 321 | 0.140 |
Why?
|
| Allergy and Immunology | 2 | 2011 | 17 | 0.140 |
Why?
|
| Diphenhydramine | 3 | 1993 | 16 | 0.140 |
Why?
|
| Telemedicine | 2 | 2019 | 229 | 0.140 |
Why?
|
| Triamcinolone Acetonide | 2 | 1998 | 8 | 0.140 |
Why?
|
| Airway Obstruction | 2 | 2011 | 117 | 0.140 |
Why?
|
| Community Health Services | 1 | 2019 | 81 | 0.140 |
Why?
|
| Aerosols | 5 | 2011 | 48 | 0.140 |
Why?
|
| SRS-A | 14 | 1989 | 27 | 0.140 |
Why?
|
| Respiratory Mucosa | 2 | 2013 | 90 | 0.130 |
Why?
|
| Pregnancy | 2 | 2022 | 3237 | 0.130 |
Why?
|
| Antibody Formation | 4 | 1997 | 181 | 0.130 |
Why?
|
| Carcinoma | 1 | 2000 | 444 | 0.130 |
Why?
|
| Smoking | 2 | 2016 | 649 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2008 | 1878 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.130 |
Why?
|
| Platelet Activating Factor | 3 | 1994 | 53 | 0.130 |
Why?
|
| Combined Modality Therapy | 4 | 2006 | 1739 | 0.130 |
Why?
|
| Respiratory Therapy | 1 | 1997 | 17 | 0.130 |
Why?
|
| Codeine | 1 | 2016 | 12 | 0.130 |
Why?
|
| Theophylline | 3 | 1987 | 34 | 0.130 |
Why?
|
| Omalizumab | 2 | 2021 | 8 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2020 | 386 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 2 | 2002 | 1087 | 0.120 |
Why?
|
| Cyclopropanes | 5 | 2010 | 27 | 0.120 |
Why?
|
| Hypertelorism | 1 | 2016 | 1 | 0.120 |
Why?
|
| Cilia | 1 | 2016 | 29 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 47 | 0.120 |
Why?
|
| CD8 Antigens | 2 | 2006 | 84 | 0.120 |
Why?
|
| CD4 Antigens | 2 | 2006 | 82 | 0.120 |
Why?
|
| Respiration | 3 | 2000 | 281 | 0.120 |
Why?
|
| Sulfides | 5 | 2010 | 69 | 0.120 |
Why?
|
| Hypersensitivity, Delayed | 3 | 1990 | 25 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2016 | 69 | 0.120 |
Why?
|
| CD11b Antigen | 2 | 2006 | 38 | 0.120 |
Why?
|
| Growth Disorders | 1 | 1996 | 66 | 0.120 |
Why?
|
| Probability | 2 | 2008 | 364 | 0.120 |
Why?
|
| Benzhydryl Compounds | 3 | 1990 | 45 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 500 | 0.120 |
Why?
|
| Autoimmune Diseases | 2 | 2016 | 257 | 0.120 |
Why?
|
| Muscarinic Antagonists | 1 | 1996 | 61 | 0.120 |
Why?
|
| Facial Pain | 1 | 2015 | 12 | 0.120 |
Why?
|
| Reference Values | 4 | 2013 | 674 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.110 |
Why?
|
| Choanal Atresia | 1 | 1994 | 2 | 0.110 |
Why?
|
| Vision Disorders | 1 | 2015 | 72 | 0.110 |
Why?
|
| Ketotifen | 2 | 1993 | 3 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 1999 | 353 | 0.110 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 121 | 0.110 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 41 | 0.110 |
Why?
|
| Child, Preschool | 10 | 2010 | 3970 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 4 | 1997 | 176 | 0.110 |
Why?
|
| Nasal Septal Perforation | 1 | 2014 | 3 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2015 | 126 | 0.110 |
Why?
|
| Seasons | 5 | 1997 | 246 | 0.110 |
Why?
|
| Eosinophil Granule Proteins | 3 | 2001 | 20 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 880 | 0.100 |
Why?
|
| Mucous Membrane | 3 | 2001 | 85 | 0.100 |
Why?
|
| Skin Tests | 9 | 2010 | 46 | 0.100 |
Why?
|
| Prostaglandins | 3 | 1996 | 44 | 0.100 |
Why?
|
| Nasopharynx | 3 | 2021 | 51 | 0.100 |
Why?
|
| Histamine H2 Antagonists | 1 | 1993 | 13 | 0.100 |
Why?
|
| Television | 1 | 2013 | 29 | 0.100 |
Why?
|
| Medical History Taking | 1 | 2013 | 88 | 0.100 |
Why?
|
| Prevalence | 4 | 2012 | 1349 | 0.100 |
Why?
|
| Genome, Human | 2 | 2008 | 824 | 0.100 |
Why?
|
| Cynodon | 1 | 2013 | 2 | 0.100 |
Why?
|
| Endo-1,4-beta Xylanases | 1 | 2013 | 3 | 0.100 |
Why?
|
| Injections, Intraocular | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cysteine Proteases | 1 | 2013 | 4 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2013 | 234 | 0.100 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2006 | 69 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2013 | 3904 | 0.100 |
Why?
|
| Leukocytes | 3 | 2001 | 213 | 0.100 |
Why?
|
| Environmental Health | 1 | 1992 | 10 | 0.090 |
Why?
|
| Immune System | 1 | 1993 | 103 | 0.090 |
Why?
|
| Immersion | 2 | 2003 | 22 | 0.090 |
Why?
|
| Immunoglobulin G | 6 | 1997 | 481 | 0.090 |
Why?
|
| Urticaria | 4 | 2024 | 15 | 0.090 |
Why?
|
| Antigens, Plant | 6 | 2011 | 15 | 0.090 |
Why?
|
| Anesthesia, Local | 2 | 1993 | 28 | 0.090 |
Why?
|
| Surgical Flaps | 1 | 2014 | 259 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 513 | 0.090 |
Why?
|
| Acetaminophen | 1 | 1992 | 61 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 220 | 0.090 |
Why?
|
| Antibody Specificity | 3 | 1997 | 128 | 0.090 |
Why?
|
| Dose-Response Relationship, Immunologic | 8 | 2007 | 42 | 0.090 |
Why?
|
| Adjuvants, Anesthesia | 1 | 1991 | 4 | 0.090 |
Why?
|
| Allergists | 2 | 2021 | 5 | 0.080 |
Why?
|
| Phenols | 1 | 1991 | 42 | 0.080 |
Why?
|
| Air Pollutants | 1 | 1992 | 109 | 0.080 |
Why?
|
| Hypertonic Solutions | 1 | 1990 | 17 | 0.080 |
Why?
|
| Pulmonary Medicine | 1 | 2011 | 51 | 0.080 |
Why?
|
| Trees | 1 | 2011 | 46 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 290 | 0.080 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2011 | 68 | 0.080 |
Why?
|
| Cells, Cultured | 4 | 2013 | 2929 | 0.080 |
Why?
|
| Phenylbutyrates | 1 | 1990 | 9 | 0.080 |
Why?
|
| Carbon Dioxide | 1 | 2011 | 212 | 0.080 |
Why?
|
| Cell Count | 4 | 1991 | 202 | 0.080 |
Why?
|
| Lidocaine | 3 | 2003 | 67 | 0.080 |
Why?
|
| Plant Extracts | 2 | 2008 | 248 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 104 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2020 | 667 | 0.080 |
Why?
|
| Forecasting | 1 | 2011 | 317 | 0.080 |
Why?
|
| Anesthesia, General | 1 | 1991 | 127 | 0.080 |
Why?
|
| Cell Movement | 5 | 1998 | 816 | 0.080 |
Why?
|
| Genetic Linkage | 2 | 2008 | 620 | 0.080 |
Why?
|
| Nose Diseases | 1 | 2009 | 9 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 857 | 0.080 |
Why?
|
| Neurotoxins | 1 | 1989 | 48 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1463 | 0.080 |
Why?
|
| Blood Flow Velocity | 1 | 1990 | 201 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2009 | 21 | 0.070 |
Why?
|
| Epithelium | 3 | 1998 | 322 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 2473 | 0.070 |
Why?
|
| Recurrence | 4 | 1997 | 1211 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2008 | 40 | 0.070 |
Why?
|
| Disease Management | 3 | 2019 | 360 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2013 | 705 | 0.070 |
Why?
|
| Biopsy, Needle | 2 | 2002 | 231 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2015 | 10273 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2008 | 80 | 0.070 |
Why?
|
| Tosylarginine Methyl Ester | 4 | 1994 | 5 | 0.070 |
Why?
|
| Osmolar Concentration | 5 | 1992 | 180 | 0.070 |
Why?
|
| Exudates and Transudates | 1 | 1988 | 13 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1008 | 0.070 |
Why?
|
| Tryptases | 3 | 2002 | 11 | 0.070 |
Why?
|
| Pharyngitis | 1 | 1988 | 15 | 0.070 |
Why?
|
| Leukotriene B4 | 4 | 1996 | 16 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1176 | 0.070 |
Why?
|
| Lacrimal Apparatus | 1 | 2008 | 11 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2008 | 47 | 0.070 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 1998 | 58 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2012 | 480 | 0.070 |
Why?
|
| Arachidonic Acids | 2 | 1987 | 37 | 0.070 |
Why?
|
| Regional Blood Flow | 2 | 2003 | 197 | 0.070 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2008 | 77 | 0.070 |
Why?
|
| Hydroxycorticosteroids | 1 | 2007 | 2 | 0.070 |
Why?
|
| Adoptive Transfer | 2 | 2005 | 175 | 0.070 |
Why?
|
| Xerostomia | 1 | 2007 | 10 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 83 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 2882 | 0.070 |
Why?
|
| Receptors, Histamine H1 | 2 | 2000 | 8 | 0.070 |
Why?
|
| Urban Population | 1 | 2008 | 240 | 0.060 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 286 | 0.060 |
Why?
|
| Siblings | 1 | 2007 | 109 | 0.060 |
Why?
|
| Olfaction Disorders | 1 | 2008 | 77 | 0.060 |
Why?
|
| Sheep | 1 | 2007 | 250 | 0.060 |
Why?
|
| Sendai virus | 1 | 2006 | 8 | 0.060 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2006 | 84 | 0.060 |
Why?
|
| Ethmoid Sinus | 2 | 2025 | 7 | 0.060 |
Why?
|
| Chicago | 1 | 2011 | 1505 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2006 | 20 | 0.060 |
Why?
|
| Muscarinic Agonists | 2 | 1996 | 23 | 0.060 |
Why?
|
| Mucus | 2 | 1987 | 19 | 0.060 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2006 | 34 | 0.060 |
Why?
|
| Environment | 1 | 2008 | 231 | 0.060 |
Why?
|
| Glycolipids | 1 | 2005 | 30 | 0.060 |
Why?
|
| Rhinovirus | 3 | 1990 | 29 | 0.060 |
Why?
|
| Rabbits | 1 | 2007 | 639 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2005 | 136 | 0.060 |
Why?
|
| Headache | 1 | 2006 | 82 | 0.060 |
Why?
|
| Chymases | 2 | 1996 | 10 | 0.060 |
Why?
|
| Osteoma, Osteoid | 1 | 1985 | 8 | 0.060 |
Why?
|
| Drug Implants | 1 | 2025 | 40 | 0.060 |
Why?
|
| Gene Regulatory Networks | 1 | 2008 | 322 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 372 | 0.060 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 1998 | 40 | 0.060 |
Why?
|
| Placebo Effect | 1 | 2005 | 35 | 0.060 |
Why?
|
| Facial Paralysis | 1 | 1985 | 23 | 0.060 |
Why?
|
| Temporal Bone | 1 | 1985 | 61 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2008 | 565 | 0.050 |
Why?
|
| Kinetics | 3 | 1999 | 1561 | 0.050 |
Why?
|
| Tachyphylaxis | 3 | 1994 | 14 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 7215 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2006 | 2161 | 0.050 |
Why?
|
| Phospholipases A | 2 | 1994 | 45 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2006 | 378 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2014 | 936 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2024 | 80 | 0.050 |
Why?
|
| Cell Separation | 3 | 2014 | 205 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2013 | 41 | 0.050 |
Why?
|
| Radioallergosorbent Test | 4 | 1993 | 8 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2013 | 430 | 0.050 |
Why?
|
| Paranasal Sinus Diseases | 2 | 2013 | 20 | 0.050 |
Why?
|
| Penicillins | 1 | 1983 | 24 | 0.050 |
Why?
|
| Kininogens | 4 | 1986 | 6 | 0.050 |
Why?
|
| Stem Cells | 1 | 2005 | 394 | 0.050 |
Why?
|
| Drug Hypersensitivity | 1 | 1983 | 40 | 0.050 |
Why?
|
| Prognosis | 3 | 2013 | 3990 | 0.050 |
Why?
|
| Sympathetic Nervous System | 1 | 2003 | 99 | 0.050 |
Why?
|
| Lactoferrin | 3 | 1998 | 11 | 0.050 |
Why?
|
| DNA | 1 | 2008 | 1327 | 0.050 |
Why?
|
| Lymphocytes | 1 | 1985 | 465 | 0.050 |
Why?
|
| Nebulizers and Vaporizers | 2 | 1994 | 62 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 84 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 1983 | 55 | 0.050 |
Why?
|
| Mass Screening | 1 | 2007 | 710 | 0.050 |
Why?
|
| Drug Liberation | 1 | 2022 | 18 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 1985 | 316 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 489 | 0.050 |
Why?
|
| Capsaicin | 3 | 1999 | 45 | 0.050 |
Why?
|
| Pedigree | 3 | 2008 | 977 | 0.050 |
Why?
|
| Neuropeptides | 2 | 1999 | 116 | 0.040 |
Why?
|
| Ozone | 2 | 1992 | 12 | 0.040 |
Why?
|
| Information Technology | 1 | 2021 | 4 | 0.040 |
Why?
|
| Tympanoplasty | 1 | 1981 | 13 | 0.040 |
Why?
|
| Air Conditioning | 1 | 2001 | 6 | 0.040 |
Why?
|
| Mastoid | 1 | 1981 | 16 | 0.040 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2001 | 13 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2001 | 92 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 97 | 0.040 |
Why?
|
| Acoustics | 1 | 2001 | 51 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2002 | 325 | 0.040 |
Why?
|
| Workload | 1 | 2001 | 133 | 0.040 |
Why?
|
| Glottis | 1 | 1980 | 13 | 0.040 |
Why?
|
| Atrophy | 1 | 2001 | 131 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 2039 | 0.040 |
Why?
|
| World Health Organization | 2 | 2012 | 122 | 0.040 |
Why?
|
| Masks | 1 | 2000 | 31 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 164 | 0.040 |
Why?
|
| Histamine Antagonists | 2 | 1991 | 14 | 0.040 |
Why?
|
| Laryngeal Neoplasms | 1 | 1980 | 89 | 0.040 |
Why?
|
| Aspirin | 4 | 1991 | 169 | 0.040 |
Why?
|
| Triage | 1 | 2021 | 132 | 0.040 |
Why?
|
| Immunization | 2 | 1998 | 165 | 0.040 |
Why?
|
| Otitis Media with Effusion | 2 | 1992 | 6 | 0.040 |
Why?
|
| Infant | 5 | 1994 | 3360 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2001 | 207 | 0.040 |
Why?
|
| Pharmacists | 1 | 2019 | 36 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2000 | 112 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 933 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 25 | 0.040 |
Why?
|
| Immunity, Cellular | 3 | 1991 | 189 | 0.040 |
Why?
|
| Professional Role | 1 | 2019 | 42 | 0.040 |
Why?
|
| Drug Evaluation | 2 | 1992 | 127 | 0.040 |
Why?
|
| Bacteria | 2 | 2014 | 517 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 71 | 0.040 |
Why?
|
| Administration, Inhalation | 2 | 1997 | 203 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 241 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 307 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 1997 | 6 | 0.030 |
Why?
|
| Adenoma | 1 | 1980 | 260 | 0.030 |
Why?
|
| Medical Records | 1 | 2018 | 125 | 0.030 |
Why?
|
| Fluocinolone Acetonide | 2 | 1988 | 8 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 122 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 123 | 0.030 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2017 | 2 | 0.030 |
Why?
|
| Clemastine | 1 | 1997 | 2 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2017 | 36 | 0.030 |
Why?
|
| Peroxidases | 1 | 1997 | 34 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 64 | 0.030 |
Why?
|
| Albuterol | 1 | 1997 | 35 | 0.030 |
Why?
|
| Nasal Surgical Procedures | 1 | 2016 | 9 | 0.030 |
Why?
|
| Dinoprost | 1 | 1996 | 27 | 0.030 |
Why?
|
| Endothelium | 1 | 1997 | 60 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 75 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 74 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1997 | 93 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 682 | 0.030 |
Why?
|
| Kallikreins | 2 | 1986 | 46 | 0.030 |
Why?
|
| Receptors, Neurotransmitter | 3 | 1991 | 25 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 1997 | 68 | 0.030 |
Why?
|
| Nerve Endings | 1 | 1996 | 16 | 0.030 |
Why?
|
| Sphenoid Sinus | 1 | 1995 | 9 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 50 | 0.030 |
Why?
|
| Age Factors | 2 | 1998 | 1957 | 0.030 |
Why?
|
| Web Browser | 1 | 2015 | 5 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 134 | 0.030 |
Why?
|
| Lung | 6 | 2008 | 1380 | 0.030 |
Why?
|
| Health Planning | 1 | 2015 | 18 | 0.030 |
Why?
|
| Treatment Failure | 1 | 1996 | 297 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 1080 | 0.030 |
Why?
|
| Medical Informatics | 1 | 2015 | 48 | 0.030 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 1994 | 7 | 0.030 |
Why?
|
| Mucocele | 1 | 1994 | 5 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 307 | 0.030 |
Why?
|
| Fascia Lata | 1 | 2014 | 7 | 0.030 |
Why?
|
| Acute-Phase Reaction | 1 | 1994 | 16 | 0.030 |
Why?
|
| Rhinometry, Acoustic | 1 | 2014 | 3 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2014 | 52 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 71 | 0.030 |
Why?
|
| Cartilage | 1 | 2014 | 116 | 0.030 |
Why?
|
| Mannitol | 2 | 1992 | 51 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 1987 | 311 | 0.030 |
Why?
|
| Frontal Sinusitis | 1 | 1993 | 2 | 0.030 |
Why?
|
| Sphenoid Sinusitis | 1 | 1993 | 2 | 0.030 |
Why?
|
| Ethmoid Sinusitis | 1 | 1993 | 4 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 2480 | 0.030 |
Why?
|
| Cephalometry | 1 | 1993 | 49 | 0.030 |
Why?
|
| Patient Care | 2 | 2004 | 101 | 0.030 |
Why?
|
| Guidelines as Topic | 2 | 2004 | 169 | 0.030 |
Why?
|
| Health Policy | 1 | 2015 | 208 | 0.030 |
Why?
|
| Receptors, Cholinergic | 1 | 1993 | 77 | 0.020 |
Why?
|
| Anesthetics, Intravenous | 1 | 2013 | 43 | 0.020 |
Why?
|
| Chemical Fractionation | 1 | 2013 | 6 | 0.020 |
Why?
|
| Paper | 1 | 1992 | 12 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 1995 | 252 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 180 | 0.020 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 296 | 0.020 |
Why?
|
| Linear Models | 1 | 1994 | 438 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 306 | 0.020 |
Why?
|
| Filtration | 1 | 1992 | 27 | 0.020 |
Why?
|
| Americas | 1 | 2012 | 20 | 0.020 |
Why?
|
| Esterases | 1 | 1992 | 13 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 138 | 0.020 |
Why?
|
| Blood Circulation | 1 | 2012 | 31 | 0.020 |
Why?
|
| Solvents | 1 | 2013 | 90 | 0.020 |
Why?
|
| Orbital Diseases | 1 | 1992 | 15 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2013 | 121 | 0.020 |
Why?
|
| Asia | 1 | 2012 | 105 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 168 | 0.020 |
Why?
|
| Operative Time | 1 | 2013 | 167 | 0.020 |
Why?
|
| Anesthetics, Inhalation | 1 | 2013 | 102 | 0.020 |
Why?
|
| Patch Tests | 1 | 1992 | 4 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 2605 | 0.020 |
Why?
|
| Tympanic Membrane | 1 | 1992 | 13 | 0.020 |
Why?
|
| Otitis Media | 1 | 1992 | 20 | 0.020 |
Why?
|
| Sleep Stages | 1 | 1992 | 47 | 0.020 |
Why?
|
| Risk Factors | 3 | 2013 | 5961 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 349 | 0.020 |
Why?
|
| Bodily Secretions | 1 | 2011 | 3 | 0.020 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1992 | 106 | 0.020 |
Why?
|
| Peroxidase | 1 | 1991 | 54 | 0.020 |
Why?
|
| Crying | 1 | 1991 | 5 | 0.020 |
Why?
|
| Models, Biological | 3 | 1995 | 1809 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 292 | 0.020 |
Why?
|
| Midazolam | 1 | 1991 | 49 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1991 | 11 | 0.020 |
Why?
|
| Phenol | 1 | 1991 | 7 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1992 | 192 | 0.020 |
Why?
|
| Chromatography, Gas | 1 | 1991 | 28 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 376 | 0.020 |
Why?
|
| Cedrus | 1 | 2010 | 2 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1991 | 37 | 0.020 |
Why?
|
| Dermatitis, Atopic | 1 | 2012 | 66 | 0.020 |
Why?
|
| Picornaviridae Infections | 1 | 1990 | 7 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 1991 | 31 | 0.020 |
Why?
|
| Planning Techniques | 1 | 2010 | 11 | 0.020 |
Why?
|
| Skin | 2 | 1991 | 605 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 1997 | 2611 | 0.020 |
Why?
|
| Agnosia | 1 | 2010 | 6 | 0.020 |
Why?
|
| Xenon Radioisotopes | 1 | 1990 | 10 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 422 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 1991 | 205 | 0.020 |
Why?
|
| Captopril | 1 | 1990 | 23 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1989 | 16 | 0.020 |
Why?
|
| In Vitro Techniques | 6 | 1990 | 1008 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 810 | 0.020 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 1989 | 2 | 0.020 |
Why?
|
| Arachidonic Acid | 2 | 1987 | 65 | 0.020 |
Why?
|
| Capillaries | 1 | 1990 | 85 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 2342 | 0.020 |
Why?
|
| Neurons | 1 | 1998 | 1653 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2009 | 136 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 157 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1560 | 0.020 |
Why?
|
| Movement | 1 | 1991 | 324 | 0.020 |
Why?
|
| Calcium Channels | 1 | 1989 | 183 | 0.020 |
Why?
|
| Serotonin | 1 | 1989 | 219 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 517 | 0.020 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2008 | 57 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 348 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 3040 | 0.020 |
Why?
|
| Heart Rate | 1 | 1991 | 518 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 340 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1988 | 23 | 0.020 |
Why?
|
| Dopamine | 1 | 1989 | 283 | 0.020 |
Why?
|
| Plethysmography | 1 | 2008 | 18 | 0.020 |
Why?
|
| South Dakota | 1 | 2008 | 47 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2008 | 70 | 0.020 |
Why?
|
| Body Fluids | 1 | 1988 | 35 | 0.020 |
Why?
|
| Methylhistidines | 1 | 1987 | 2 | 0.020 |
Why?
|
| Histidine Decarboxylase | 1 | 1987 | 6 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 816 | 0.020 |
Why?
|
| Carboxy-Lyases | 1 | 1987 | 22 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 232 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2008 | 202 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 118 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1988 | 211 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 218 | 0.020 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1987 | 5 | 0.020 |
Why?
|
| Thromboxanes | 1 | 1987 | 7 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 1987 | 19 | 0.020 |
Why?
|
| Histidine | 1 | 1987 | 75 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 797 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1999 | 3639 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1991 | 926 | 0.020 |
Why?
|
| Tears | 2 | 1998 | 8 | 0.020 |
Why?
|
| Exocytosis | 1 | 1987 | 110 | 0.020 |
Why?
|
| Molecular Weight | 4 | 1987 | 329 | 0.020 |
Why?
|
| Cost of Illness | 2 | 1997 | 161 | 0.020 |
Why?
|
| Global Health | 1 | 2008 | 213 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 3581 | 0.010 |
Why?
|
| Radioimmunoassay | 3 | 1992 | 150 | 0.010 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 1985 | 9 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1988 | 348 | 0.010 |
Why?
|
| Receptors, Bradykinin | 3 | 1991 | 12 | 0.010 |
Why?
|
| Genes, RAG-1 | 1 | 2005 | 13 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 1986 | 72 | 0.010 |
Why?
|
| Lymphokines | 1 | 1985 | 75 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 2061 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 2480 | 0.010 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 1985 | 52 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1805 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 829 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1985 | 38 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 1714 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 68 | 0.010 |
Why?
|
| Radiography | 1 | 1985 | 823 | 0.010 |
Why?
|
| Pruritus | 1 | 2002 | 30 | 0.010 |
Why?
|
| Aging | 1 | 2008 | 766 | 0.010 |
Why?
|
| Estrogens | 1 | 1983 | 202 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 310 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 435 | 0.010 |
Why?
|
| Otitis Media, Suppurative | 1 | 1981 | 4 | 0.010 |
Why?
|
| Cholesteatoma | 1 | 1981 | 7 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1992 | 2592 | 0.010 |
Why?
|
| Ear Canal | 1 | 1981 | 17 | 0.010 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1981 | 23 | 0.010 |
Why?
|
| Ear Diseases | 1 | 1981 | 21 | 0.010 |
Why?
|
| Granuloma | 1 | 1981 | 65 | 0.010 |
Why?
|
| Proteins | 2 | 1998 | 816 | 0.010 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1981 | 47 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 760 | 0.010 |
Why?
|
| Hearing | 1 | 1981 | 64 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1992 | 380 | 0.010 |
Why?
|
| Neurokinin A | 1 | 1999 | 12 | 0.010 |
Why?
|
| Chromatography, Gel | 2 | 1992 | 105 | 0.010 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1999 | 40 | 0.010 |
Why?
|
| Substance P | 1 | 1999 | 62 | 0.010 |
Why?
|
| Cholesterol | 1 | 1981 | 366 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 1990 | 35 | 0.010 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 1998 | 11 | 0.010 |
Why?
|
| Eosinophil Peroxidase | 1 | 1997 | 14 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 39 | 0.010 |
Why?
|
| Fever | 1 | 1998 | 131 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1996 | 18 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1997 | 104 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 4374 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1996 | 102 | 0.010 |
Why?
|
| Leukotriene E4 | 2 | 1986 | 3 | 0.010 |
Why?
|
| E-Selectin | 1 | 1994 | 31 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1994 | 76 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1994 | 11 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1994 | 25 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 1994 | 44 | 0.010 |
Why?
|
| Arthritis | 1 | 1994 | 53 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 564 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1994 | 1006 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1994 | 740 | 0.010 |
Why?
|
| Preanesthetic Medication | 1 | 1991 | 5 | 0.010 |
Why?
|
| Administration, Rectal | 1 | 1991 | 13 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1992 | 599 | 0.010 |
Why?
|
| Anesthesia Recovery Period | 1 | 1991 | 55 | 0.010 |
Why?
|
| Capsules | 1 | 1990 | 38 | 0.010 |
Why?
|
| Ear, Middle | 1 | 1990 | 26 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1991 | 245 | 0.010 |
Why?
|
| Pressure | 1 | 1990 | 175 | 0.000 |
Why?
|
| Phytotherapy | 1 | 1989 | 138 | 0.000 |
Why?
|
| Isotonic Solutions | 1 | 1988 | 18 | 0.000 |
Why?
|
| Intradermal Tests | 1 | 1987 | 3 | 0.000 |
Why?
|
| Endoscopes | 1 | 1987 | 10 | 0.000 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1987 | 85 | 0.000 |
Why?
|
| Colchicine | 1 | 1987 | 20 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1991 | 775 | 0.000 |
Why?
|
| Aminopeptidases | 1 | 1987 | 14 | 0.000 |
Why?
|
| Carboxypeptidases | 1 | 1987 | 34 | 0.000 |
Why?
|
| Tissue Kallikreins | 1 | 1986 | 1 | 0.000 |
Why?
|
| Immune Sera | 1 | 1986 | 53 | 0.000 |
Why?
|
| Chromatography, Affinity | 1 | 1986 | 84 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1986 | 115 | 0.000 |
Why?
|
| Physical Stimulation | 1 | 1986 | 76 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1988 | 356 | 0.000 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 1985 | 5 | 0.000 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1985 | 40 | 0.000 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1985 | 36 | 0.000 |
Why?
|
| Physical Exertion | 1 | 1984 | 39 | 0.000 |
Why?
|
| Calcium | 1 | 1987 | 1205 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1985 | 825 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1981 | 2042 | 0.000 |
Why?
|